Regarding the PC group, eight patients (53.3%) received anti-IL-17 biologics, six patients (40%) were treated with anti-IL-23 agents, and one patient (6.7%) received treatment with anti-IL-12/23. The gene discussed is IL23A; the disease is pachyonychia congenita.